The UNMC College of Medicine received new grant and funding awards representing $6,868,743 in new funding in November.
- Jana Broadhurst, MD, PhD, pathology and microbiology, received a grant of $225,265 from the National Strategic Research Institute for independent verification and validation pipeline.
- Pierre Fayad, MD, neurological sciences, received a grant of $10,213 from the University of Cincinnati to study anticoagulaton in intracerebral hemorrhage (ICH) survivors for stroke and recovery (ASPIRE).
- Diana Florescu, MD, internal medicine-infectious diseases, received a grant of $3,832,501 from the Fred Hutchinson Cancer Research Center for a phase 3 study to evaluate the efficacy, safety, and immunogencitiy of SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-rS) with matrix M1 adjuvant in adult participants older than 18 years.
- Rebecca Deegan, PhD, biochemistry and molecular biology, received a NASA Nebraska Space Grant Fellowship with an award of $7,500.
- Stacey Gilk, PhD, pathology/microbiology, received a grant of $359,036 from DHHS/NIH/AID to study coxiella manipulation of cholesterol in the intracellular niche.
- Jason MacTaggart, MD, surgery-vascular surgery, received a grant of $166,309 from the University of Nebraska at Omaha for optimized stents for the femoropopliteal artery.
- Sidharth Mahapatra, MD, PhD, pediatrics critical care, received a grant of $57,954 from the Nebraska DHHS for a study of NFIB’s role in medulloblastoma stem cell renewal; and a grant of $23,000 from the University of Pennsylvania for PROSpect (Prone and Oscillation Pediatric Clinical Trial).
- James McClay, MD, emergency medicine, received a grant of $180,921 from West Virginia University for the IDeA clinical and translational research units join the National COVID Cohort Collaborative.
- Alicia Schiller, PhD, anesthesiology, received a grant of $107,206 from the National Strategic Research Institute for the assessment and training of procedural skills for combat casualty care.
- Christopher Smith, MD, internal medicine-hospital medicine, received a grant of $2,420 from Oregon Health and Science University for Just in Time! Evaluating the effect of a structured training on resident point-of-care ultrasound use.
Industry-sponsored grants and contracts:
The following industry-sponsored contracts and foundation grants were received. Information on clinical trials enrolling patients at UNMC can be found here.
- Cyrus Desouza, MBBS, internal medicine-DEM, received funding for a 78-week trial comparing the effect and safety of once-weekly insulin icodec and once-daily insulin glargine.
- Andjela Drincic, MD, internal medicine-DEM, received funding for the Management of Acromegaly (MACRO) Registry.
- Diana Florescu, MD, internal medicine-infectious diseases, received funding for a phase 2/3, randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy, safety and pharmacokinetics of MK-4482 in hospitalized adults with COVID-19; funding for a phase 2/3, randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy, safety and pharmacokinetics of MK-4482 in non-hospitalized adults with COVID-19 ; and funding for a phase 2, randomized, double-blind, placebo-controlled study of NPC-21 for kidney transplant recipients at high risk of cytomegalovirus infection.
- Scott Koepsell, MD, PhD, pathology/microbiology, received funding for a medical advisor agreement.
- Russell McCulloh, MD, pediatrics hospitalists, received funding for CoVPN 3501: Eli Lilly (LY3819253) – protocol funding.
- Nicole Shonka, MD, internal medicine-oncology/hematology, received funding for a study of ANG1005 compared with physician’s best choice in HER2-negative breast cancer patients with newly diagnosed leptomeningeal carcinomatosis and previously treated brain metastases.
- Erica Stohs, MD, internal medicine-infectious diseases, received funding for a trial of the safety, tolerability and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation with a documented upper respiratory tract infection.
- Vijay Shivaswamy, MBBS, internal medicine-DEM, received funding to study the effect of tirzepatide versus dulaglutide on major cardiovascular events in patients with type 2 diabetes.